Furthermore, half of the “prostate cancer” pathway DEGsSD are well described in the PCa literature (AR, CDKN1A, CTNNB1, EGFR, KLK2, NKX3-1, PDGFRA, SRD5A2), confirming that this is a pivotal pathway to specifically target clinical questions on canine PCa. Here, AR is linked to prostate cancer.